NCT06564233 Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
| NCT ID | NCT06564233 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Victor Wang |
| Condition | Hematopoietic Stem Cell Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-10-21 |
| Primary Completion | 2026-09-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-10-21 with a primary completion date of 2026-09-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this study is to assess the efficacy of the care.coach Avatar™ in improving anxiety and quality of life for patients undergoing outpatient transplant. After care.coach Avatar™ content and scheduling ("digital intervention" or "program") has been optimized for outpatient allogeneic hematopoietic stem cell transplantation (HCT), a randomized controlled trial (RCT) will be conducted of the digital versus usual supportive care program for outpatient HCT recipients. Potential improvements in anxiety and quality of life will be evaluated, with the intent of increasing comfortability with outpatient transplant and expanding the population of eligible patients willing to receive their transplants in an outpatient setting.
Eligibility Criteria
Inclusion Criteria: * Age 18+ * Seen for outpatient RIC HCT (prior to D0, generally D-6). Exclusion Criteria: * Deemed by clinical staff or research assistant (RA) to be unable to converse with an avatar, due to: severe, uncorrectable hearing or vision impairment; severe speech impairment that precludes understanding by staff (or by the avatar). * Not fluent in English.
Contact & Investigator
Victor Wang, MS
PRINCIPAL INVESTIGATOR
Friendi.fi Corporation
Frequently Asked Questions
Who can join the NCT06564233 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06564233 currently recruiting?
Yes, NCT06564233 is actively recruiting participants. Contact the research team at chantal@friendi.fi for enrollment information.
Where is the NCT06564233 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06564233 clinical trial?
NCT06564233 is sponsored by Victor Wang. The principal investigator is Victor Wang, MS at Friendi.fi Corporation. The trial plans to enroll 90 participants.